Equities Analysts Offer Predictions for IDXX FY2026 Earnings

IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) - Analysts at Leerink Partnrs dropped their FY2026 EPS estimates for shares of IDEXX Laboratories in a report released on Monday, April 21st. Leerink Partnrs analyst D. Clark now expects that the company will post earnings per share of $13.64 for the year, down from their prior estimate of $13.80. The consensus estimate for IDEXX Laboratories' current full-year earnings is $11.93 per share.

Several other equities research analysts have also weighed in on the company. Stifel Nicolaus cut their target price on IDEXX Laboratories from $450.00 to $420.00 and set a "hold" rating on the stock in a research report on Monday, April 14th. Morgan Stanley cut their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating on the stock in a report on Wednesday, January 29th. Barclays upped their target price on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a report on Tuesday, February 4th. Bank of America lifted their price target on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a research note on Tuesday, February 4th. Finally, Piper Sandler upped their price objective on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a research note on Monday, February 10th. Four equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $523.75.

IDEXX Laboratories Stock Up 3.7 %

IDEXX Laboratories stock opened at $421.59 on Wednesday. The stock has a market cap of $34.17 billion, a PE ratio of 39.51, a P/E/G ratio of 3.41 and a beta of 1.50. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. The stock's fifty day moving average is $420.59 and its two-hundred day moving average is $429.92. IDEXX Laboratories has a 1-year low of $356.14 and a 1-year high of $548.88.

Institutional Investors Weigh In On IDEXX Laboratories

A number of hedge funds have recently added to or reduced their stakes in IDXX. Geode Capital Management LLC boosted its stake in shares of IDEXX Laboratories by 1.7% in the fourth quarter. Geode Capital Management LLC now owns 2,297,271 shares of the company's stock valued at $948,279,000 after buying an additional 37,734 shares in the last quarter. Bamco Inc. NY grew its stake in shares of IDEXX Laboratories by 4.3% during the 4th quarter. Bamco Inc. NY now owns 2,005,522 shares of the company's stock worth $829,163,000 after purchasing an additional 82,264 shares during the period. Franklin Resources Inc. increased its holdings in shares of IDEXX Laboratories by 2.5% in the 3rd quarter. Franklin Resources Inc. now owns 1,412,700 shares of the company's stock valued at $675,259,000 after purchasing an additional 34,305 shares in the last quarter. Invesco Ltd. lifted its stake in shares of IDEXX Laboratories by 6.8% in the fourth quarter. Invesco Ltd. now owns 1,160,988 shares of the company's stock valued at $479,999,000 after purchasing an additional 74,324 shares during the period. Finally, Norges Bank acquired a new position in IDEXX Laboratories during the fourth quarter worth about $412,258,000. Institutional investors and hedge funds own 87.84% of the company's stock.

Insider Buying and Selling

In other news, EVP George Fennell sold 9,986 shares of the business's stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the transaction, the executive vice president now owns 8,176 shares of the company's stock, valued at approximately $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director M Anne Szostak sold 3,000 shares of the stock in a transaction on Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the sale, the director now directly owns 3,061 shares of the company's stock, valued at approximately $1,426,242.34. This represents a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.98% of the company's stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.